池昊育(綜述),劉志剛,劉曉程1, ※(審校)
(1.中國(guó)醫(yī)學(xué)科學(xué)院 北京協(xié)和醫(yī)學(xué)院,北京 100730; 2.泰達(dá)國(guó)際心血管病醫(yī)院心外科,天津 300457)
體外循環(huán)引起血小板損傷的相關(guān)因素分析
池昊育1,2△(綜述),劉志剛2,劉曉程1,2 ※(審校)
(1.中國(guó)醫(yī)學(xué)科學(xué)院 北京協(xié)和醫(yī)學(xué)院,北京 100730; 2.泰達(dá)國(guó)際心血管病醫(yī)院心外科,天津 300457)
體外循環(huán)技術(shù)是現(xiàn)代心血管外科的重大突破,是心內(nèi)直視手術(shù)必不可少的手段。隨著該技術(shù)不斷改善,體外循環(huán)帶來(lái)的并發(fā)癥逐漸減少,但體外循環(huán)后的非外科性出血仍是較常見(jiàn)的并發(fā)癥,嚴(yán)重影響患者的預(yù)后,甚至造成患者死亡。造成體外循環(huán)后凝血障礙的因素包括外科創(chuàng)傷、血液稀釋、體外循環(huán)管道內(nèi)血液與非內(nèi)皮表面的接觸、血小板功能障礙、低溫等,其中,血小板功能障礙被認(rèn)為是體外循環(huán)心內(nèi)直視手術(shù)后非外科性出血的主要原因[1]。體外循環(huán)造成血小板損傷的具體機(jī)制依然不明,對(duì)體外循環(huán)造成血小板損傷的因素與機(jī)制的探討將有助于進(jìn)行血小板保護(hù),從而降低術(shù)后非外科性出血的發(fā)生率。近年來(lái),許多學(xué)者對(duì)體外循環(huán)期間造成血小板損傷的因素進(jìn)行了一系列的實(shí)驗(yàn)與臨床研究,現(xiàn)綜述如下。
1低溫
全身中、淺低溫和心臟局部深低溫是心臟手術(shù)中心肌保護(hù)的基礎(chǔ)方法。低溫使機(jī)體的基礎(chǔ)代謝率降低,機(jī)體氧耗量減少,故體外循環(huán)灌注量降低,不僅可減輕血細(xì)胞損傷,還能增加體外循環(huán)的安全性。Speziale等[2]報(bào)道,低溫體外循環(huán)能在更大程度上引起血小板的激活和功能損傷:血小板表面P-選擇素表達(dá)明顯升高、血漿中可溶性P-選擇素釋放增加也更明顯、血小板聚集功能降低,但不論是低溫體外循環(huán),還是常溫體外循環(huán),血小板數(shù)目均無(wú)明顯改變。還有學(xué)者指出低溫體外循環(huán)導(dǎo)致的血小板聚集功能損傷是部分可逆的,即復(fù)溫后,血小板的聚集功能可部分恢復(fù)[3-4]。
關(guān)于低溫對(duì)血小板聚集功能的影響,有學(xué)者持相反觀點(diǎn)。Straub等[5]的體外實(shí)驗(yàn)顯示,低溫會(huì)誘導(dǎo)血小板聚集,在從中低溫(25~30 ℃)到深低溫(<20 ℃)范圍內(nèi),溫度變化與血小板的聚集程度呈負(fù)相關(guān)。低溫對(duì)血小板聚集功能的影響有待進(jìn)一步的實(shí)驗(yàn)研究。
Ranucci等[6]的試驗(yàn)證實(shí),體外循環(huán)過(guò)程中應(yīng)用低溫與術(shù)后遲發(fā)性血小板減少癥有關(guān),并且溫度越低,發(fā)生遲發(fā)性血小板減少癥的機(jī)會(huì)就越大。發(fā)生這一現(xiàn)象的具體機(jī)制尚未闡明,可能與低溫導(dǎo)致血小板在肝臟和脾臟內(nèi)扣押有關(guān)[7],即低溫情況下,血液流經(jīng)肝臟與脾臟時(shí),會(huì)將血小板“扣押”下來(lái),導(dǎo)致外周循環(huán)中血小板數(shù)目降低,復(fù)溫后,肝臟與脾臟的扣押作用消失,血小板重新進(jìn)入外周循環(huán)。
2血液與氣體接觸
體外循環(huán)管道中存在血液與氣體直接接觸。國(guó)內(nèi)學(xué)者認(rèn)為,在體外循環(huán)轉(zhuǎn)流中血液和氣體直接接觸會(huì)產(chǎn)生氣泡與渦流,使血液有效成分破壞,膜式氧合器能消除血液和氣體直接接觸,使血液有形成分破壞減輕[8]。但El-Sabbagh等[9]的體外實(shí)驗(yàn)指出,血液與空氣直接接觸并不會(huì)導(dǎo)致血小板激活。Pohlmann等[10]的體外實(shí)驗(yàn)也發(fā)現(xiàn),單獨(dú)的負(fù)壓吸引或氣血接觸并不會(huì)引起溶血,但是當(dāng)這個(gè)兩個(gè)因素結(jié)合時(shí)則會(huì)引起溶血。
3生物相容性
體外循環(huán)管道為人工材料,與血液的生物相容性低。血液和體外循環(huán)管道表面接觸會(huì)導(dǎo)致血小板激活與消耗[11],激活的血小板形成微栓,靜脈系統(tǒng)形成的微栓在回收過(guò)程中可被濾器過(guò)濾,而動(dòng)脈系統(tǒng)形成的微栓則聚集在患者的微循環(huán)中,加重了微循環(huán)障礙和血小板消耗[8]。因此提高體外循環(huán)管道的生物相容性成為減少術(shù)后相關(guān)并發(fā)癥的有效途徑。研究指出,肝素涂層管道[12]對(duì)血小板有保護(hù)作用、磷酰膽堿涂層的氧合器能降低手術(shù)期間凝血酶的生成以及血小板的消耗[11],聚合-2-甲基丙烯酸涂層管道[13]對(duì)于血小板也有保護(hù)作用。
4剪切力
國(guó)外學(xué)者[10]將剪切力定義為血液流動(dòng)時(shí)受到的機(jī)械作用力。Huang和Hellums[14]研究表明,剪切力大小與血小板損傷程度呈正比,且兩者的相關(guān)性在低溫下更顯著。Boonstra等[15]認(rèn)為采用心內(nèi)吸引時(shí),吸入空氣的量與剪切力大小呈正比,與血小板的激活和術(shù)后非外科性失血呈正相關(guān),并且證明防止空氣吸入的可控性心內(nèi)吸引裝置能明顯降低血小板激活和術(shù)后非外科性失血。Lau等[16]還證實(shí)在不停跳心臟搭橋時(shí)不使用心內(nèi)吸引裝置不僅不會(huì)增加術(shù)后輸血要求,還會(huì)減輕術(shù)后的全身炎癥反應(yīng),這也必然會(huì)減輕血小板損害。然而,El-Sabbagh等[9]發(fā)現(xiàn),在600 mmHg (1 mmHg=0.133 kPa)負(fù)壓的情況下吸引血液并不會(huì)激活血小板。滾軸泵擠壓管道產(chǎn)生的剪切力會(huì)損傷血液成分,而離心泵不擠壓管道,因此對(duì)血液的損傷更小,但是Kehara等[18]的實(shí)驗(yàn)證實(shí),離心泵和滾軸泵對(duì)血小板功能的損害差異無(wú)統(tǒng)計(jì)學(xué)意義。
為了減少體外循環(huán)過(guò)程中的剪切力,應(yīng)避免左心吸引負(fù)壓過(guò)大。應(yīng)用心內(nèi)吸引時(shí),把吸引器尖頭置于血面下進(jìn)行吸引,避免血液氣體同時(shí)吸入。
5魚精蛋白
肝素和魚精蛋白結(jié)合形成的肝素-魚精蛋白復(fù)合體有時(shí)可被硫酸酯酶分離,使魚精蛋白用量增加,Ortmann等[4]的實(shí)驗(yàn)表明,在體內(nèi)外實(shí)驗(yàn)中,魚精蛋白中和肝素均能引起血小板聚集功能降低。McLaughlin和Dunning[18]指出,在魚精蛋白與肝素的比例高于2.6時(shí),魚精蛋白能損害血小板功能、增加出血風(fēng)險(xiǎn)。Mochizuki等[19]則認(rèn)為,魚精蛋白與肝素的比例大于1.3∶1時(shí),就會(huì)導(dǎo)致ADP誘發(fā)的血小板聚集功能降低。Khan等[20]認(rèn)為造成血小板功能損害的魚精蛋白和肝素比例大于2∶1。Gertler等[21]的實(shí)驗(yàn)也表明,應(yīng)用魚精蛋白中和肝素之后,血小板功能會(huì)降低,并且這一損害從1∶1的比例就開(kāi)始了。Ortmann等[4]還指出,魚精蛋白造成的血小板聚集功能損傷在患者到達(dá)ICU后的1~2 h內(nèi)可恢復(fù),故在臨床工作中,對(duì)血小板功能的評(píng)價(jià)試驗(yàn)應(yīng)該在體外循環(huán)停機(jī)后尚未應(yīng)用魚精蛋白之前進(jìn)行,以避免魚精蛋白造成的血小板聚集功能暫時(shí)性降低被誤讀為血小板功能障礙。Hofmann等[22]認(rèn)為,應(yīng)用個(gè)體化的肝素與魚精蛋白管理方案,即以血液肝素濃度為標(biāo)準(zhǔn)而非激活全血凝固時(shí)間為標(biāo)準(zhǔn)來(lái)指導(dǎo)肝素與魚精蛋白的應(yīng)用(此時(shí)肝素的應(yīng)用劑量會(huì)更高,而魚精蛋白的應(yīng)用劑量會(huì)更低),能保護(hù)血小板的功能。
6肝素
肝素用于體外循環(huán)期間的全身抗凝。關(guān)于肝素激活血小板以及誘導(dǎo)血小板不可逆聚集的機(jī)制,各研究有不同看法。對(duì)于血小板的激活, Gao等[23]認(rèn)為,肝素是通過(guò)整合素αⅡbβ3介導(dǎo)的由外到內(nèi)的信號(hào)通路來(lái)增強(qiáng)血小板對(duì)其激動(dòng)劑的反應(yīng)從而激活血小板的,并提出,可應(yīng)用血小板膜糖蛋白Ⅱb/Ⅲa抑制劑來(lái)抑制非免疫性肝素誘導(dǎo)的血小板激活。對(duì)于血小板聚集功能的影響,Laga等[24]的試驗(yàn)表明,體外循環(huán)心臟手術(shù)中,應(yīng)用肝素會(huì)導(dǎo)致血小板聚集功能降低;Gallandat等[25]的研究也證明,普通肝素會(huì)影響血小板聚集功能,其可能原因?yàn)楦嗡貙?duì)血小板的不可逆激活,即肝素誘導(dǎo)血小板的釋放反應(yīng)以及隨后的不可逆聚集,此時(shí)血小板不會(huì)再被激活發(fā)生釋放反應(yīng)和聚集反應(yīng)。
7麻醉藥物的使用
目前,研究認(rèn)為靜脈麻醉藥丙泊酚會(huì)影響血小板功能。丙泊酚能抑制血小板的聚集功能[26]。Hirakata等[27]的體外實(shí)驗(yàn)證實(shí),丙泊酚對(duì)血小板聚集功能的影響取決于丙泊酚的藥物濃度:低濃度增強(qiáng),高濃度抑制,并指出,不論濃度高低,丙泊酚均不會(huì)影響血小板的第一相聚集功能。另外一種對(duì)血小板功能有影響的靜脈麻醉藥物是硫賁妥鈉,研究指出,不論體內(nèi)外,硫賁妥鈉均能使血小板的功能降低[28]。關(guān)于吸入麻醉藥,Yuki 等[29]指出,異氟烷和七氟烷能損害血小板αⅡbβ3受體的活化,而該受體的活化對(duì)于血小板的活化和血凝塊的穩(wěn)定性來(lái)說(shuō)是關(guān)鍵步驟,從而影響血小板的聚集功能和血凝塊的穩(wěn)定。
8體外循環(huán)機(jī)血液回輸
Kongsgaard等[30]對(duì)體外循環(huán)機(jī)血液中的血小板進(jìn)行研究發(fā)現(xiàn),機(jī)血中大部分血小板由正常的圓盤狀變?yōu)榍蛐?,并且缺少?顆粒和致密體——這些物質(zhì)的缺乏是血小板不可逆活化的標(biāo)志。De Somer等[31]的實(shí)驗(yàn)表明,相比將回吸的血液丟棄,機(jī)血回輸會(huì)引起明顯的血小板激活。Lau等[16]指出,從心包腔內(nèi)回吸的血液,其凝血因子激活、炎癥反應(yīng)標(biāo)志物水平升高、血小板激活;這些血液回輸后,機(jī)體血漿中補(bǔ)體C3、腫瘤壞死因子和白細(xì)胞介素6相比未行機(jī)血回輸?shù)膶?duì)照組明顯升高,這使機(jī)血回輸不但不能降低血液丟失和術(shù)后輸血需求,反而會(huì)增加微循環(huán)栓塞,使術(shù)后的全身炎癥反應(yīng)增強(qiáng)。因此,Lau等[16]認(rèn)為,在冠狀動(dòng)脈旁路移植手術(shù)中,常規(guī)應(yīng)用心包血液回吸是不必要的。
9血液稀釋
體外循環(huán)中合理的血液稀釋可以改善微循環(huán)灌注,減輕酸中毒和減少體外循環(huán)多種并發(fā)癥,減少血制品用量[32]。龍村[33]認(rèn)為,血液稀釋的同時(shí),也稀釋了血液中的各種成分和血細(xì)胞,但只要能保持血小板>60×1012/L、其他凝血因子不低于正常的30%,就能保持正常的凝血功能。同時(shí)指出,血液稀釋降低了細(xì)胞濃度,能避免血小板聚集產(chǎn)生微循環(huán)阻塞,減輕體外循環(huán)對(duì)血小板的激活與消耗。
10體外循環(huán)流轉(zhuǎn)時(shí)間
研究表明,體外循環(huán)流轉(zhuǎn)時(shí)間與出血傾向呈正相關(guān)[3,33]。此外,體外循環(huán)流轉(zhuǎn)時(shí)間短時(shí),血小板的功能得到增強(qiáng),可能的機(jī)制為短時(shí)間的體外循環(huán)促進(jìn)了血小板的激活,但體外循環(huán)時(shí)間的進(jìn)一步延長(zhǎng)會(huì)導(dǎo)致血小板的耗竭[3]。Bφnding Andreasen等[3]研究認(rèn)為造成體外循環(huán)流轉(zhuǎn)時(shí)間與出血傾向呈正相關(guān)的原因與體外循環(huán)造成血小板數(shù)目及功能下降有關(guān)。因此盡量縮短體外循環(huán)轉(zhuǎn)流時(shí)間,是降低體外循環(huán)中血液破壞及術(shù)后非外科性出血發(fā)生率的重要措施。
11結(jié)語(yǔ)
體外循環(huán)造成血小板損傷的因素眾多,目前,國(guó)內(nèi)外學(xué)者圍繞體外循環(huán)引起血小板損傷的因素做了大量實(shí)驗(yàn)研究,但對(duì)各種因素造成血小板損傷的分子水平機(jī)制還缺乏了解。目前對(duì)于血小板的保護(hù)措施主要包括藥物對(duì)血小板的保護(hù)、制備富血小板血漿及自體血小板膠,但真正安全、有效且價(jià)格合理的藥物還有待開(kāi)發(fā),而制備富血小板血漿以及自體血小板膠也未在臨床廣泛應(yīng)用,體外循環(huán)造成的血小板損傷還不能有效預(yù)防。對(duì)于體外循環(huán)造成血小板損傷的相關(guān)因素和機(jī)制的進(jìn)一步了解將有助于針對(duì)性地采取血小板保護(hù)措施,從而降低術(shù)后非外科性出血的發(fā)生率。
參考文獻(xiàn)
[1]Reece MJ,Klein AA,Salviz EA,etal.Near-patient platelet function testing in patients undergoing coronary artery surgery:a pilot study[J].Anaesthesia,2011,66(2):97-103.
[2]Speziale G,Ferroni P,Ruvolo G,etal.Effect of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function[J].J Cardiovasc Surg (Torino),2000,41(6):819-827.
[3]Bφnding Andreasen J,Hvas AM,Ravn HB.Marked changes in platelet count and function following pediatric congenital heart surgery[J].Paediatr Anaesth,2014,24(4):386-392.
[4]Ortmann E,Klein AA,Sharples LD,etal.Point-of-care assessment of hypothermia and protamine-induced platelet dysfunction with multiple electrode aggregometry (Multiplate(R)) in patients undergoing cardiopulmonary bypass[J].Anesth Analg,2013,116(3):533-540.
[5]Straub A,Breuer M,Wendel HP,etal.Critical temperature ranges of hypothermia-induced platelet activation:possible implications for cooling patients in cardiac surgery[J].Thromb Haemost,2007,97(4):608-616.
[6]Ranucci M,Carlucci C,Isgro G,etal.Hypothermic cardiopulmonary bypass as a determinant of late thrombocytopenia following cardiac operations in pediatric patients[J].Acta Anaesthesiol Scand,2009,53(8):1060-1067.
[7]Vella MA,Jenner C,Betteridge DJ,etal.Hypothermia-induced thrombocytopenia[J].J R Soc Med,1988,81(10):619.
[8]林琦,覃家錦,馮旭,等.P-選擇素與體外循環(huán)關(guān)系的研究進(jìn)展[J].微創(chuàng)醫(yī)學(xué),2009,4(2):165-167.
[9]El-Sabbagh AM,Toomasian CJ,Toomasian JM,etal.Effect of air exposure and suction on blood cell activation and hemolysis in an in vitro cardiotomy suction model[J].ASAIO J,2013,59(5):474-479.
[10]Pohlmann JR,Toomasian JM,Hampton CE,etal.The relationships between air exposure,negative pressure,and hemolysis[J].ASAIO J,2009,55(5):469-473.
[11]Pappalardo F,Della VP,Crescenzi G,etal.Phosphorylcholine coating may limit thrombin formation during high-risk cardiac surgery:a randomized controlled trial[J].Ann Thorac Surg,2006,81(3):886-891.
[12]Mahmood S,Bilal H,Zaman M,etal.Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit[J].Interact Cardiovasc Thorac Surg,2012,14(4):406-414.
[13]Thiara AS,Mollnes TE,Videm V,etal.Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery[J].Perfusion,2011,26(2):107-114.
[14]Huang PY,Hellums JD.Aggregation and disaggregation kinetics of human blood platelets:Part Ⅱ.Shear-induced platelet aggregation[J].Biophys J,1993,65(1):344-353.
[15]Boonstra PW,van Imhoff GW,Eysman L,etal.Reduced platelet activation and improved hemostasis after controlled cardiotomy suction during clinical membrane oxygenator perfusions[J].J Thorac Cardiovasc Surg,1985,89(6):900-906.
[16]Lau K,Shah H,Kelleher A,etal.Coronary artery surgery:cardiotomy suction or cell salvage[J].J Cardiothorac Surg,2007,2:46.
[17]Kehara H,Takano T,Ohashi N,etal.Platelet function during cardiopulmonary bypass using multiple electrode aggregometry:comparison of centrifugal and roller pumps[J].Artif Organs,2014,38(11):924-930.
[18]McLaughlin KE,Dunning J.In patients post cardiac surgery do high doses of protamine cause increased bleeding[J].Interact Cardiovasc Thorac Surg,2003,2(4):424-426.
[19]Mochizuki T,Olson PJ,Szlam F,etal.Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass[J].Anesth Analg,1998,87(4):781-785.
[20]Khan NU,Wayne CK,Barker J,etal.The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph[J].Eur J Anaesthesiol,2010,27(7):624-627.
[21]Gertler R,Wiesner G,Tassani-Prell P,etal.Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine[J].J Cardiothorac Vasc Anesth,2011,25(6):981-986.
[22]Hofmann B,Bushnaq H,Kraus FB,etal.Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy[J].Perfusion,2013,28(5):412-418.
[23]Gao C,Boylan B,Fang J,etal.Heparin promotes platelet responsiveness by potentiating alphaIIbbeta3-mediated outside-in signaling[J].Blood,2011,117(18):4946-4952.
[24]Laga S,Bollen H,Arnout J,etal.Heparin influences human platelet behavior in cardiac surgery with or without cardiopulmonary bypass[J].Artif Organs,2005,29(7):541-546.
[25]Gallandat HRC,de Vries AJ,Cernak V,etal.Platelet function in stored heparinised autologous blood is not superior to in patient platelet function during routine cardiopulmonary bypass[J].PLoS One,2012,7(3):e33686.
[26]Vasileiou I,Xanthos T,Koudouna E,etal.Propofol:a review of its non-anaesthetic effects[J].Eur J Pharmacol,2009,605(1/3):1-8.
[27]Hirakata H,Nakamura K,Yokubol B,etal.Propofol has both enhancing and suppressing effects on human platelet aggregation in vitro[J].Anesthesiology,1999,91(5):1361-1369.
[28]Dordoni PL,Frassanito L,Bruno MF,etal.In vivo and in vitro effects of different anaesthetics on platelet function[J].Br J Haematol,2004,125(1):79-82.
[29]Yuki K,Bu W,Shimaoka M,etal.Volatile anesthetics,not intravenous anesthetic propofol bind to and attenuate the activation of platelet receptor integrin αⅡβ3[J].PLoS One,2013,8(4):e60415.
[30]Kongsgaard UE,Hovig T,Brosstad F,etal.Platelets in shed mediastinal blood used for postoperative autotransfusion[J].Acta Anaesthesiol Scand,1993,37(3):265-268.
[31]De Somer F,Van Belleghem Y,Caes F,etal.Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass[J].J Thorac Cardiovasc Surg,2002,123(5):951-958.
[32]龍村.體外循環(huán)學(xué)[M].北京:人民軍醫(yī)出版社,2004:393-395.
[33]Hayashi T,Sakurai Y,Fukuda K,etal.Correlations between global clotting function tests,duration of operation,and postoperative chest tube drainage in pediatric cardiac surgery[J].Paediatr Anaesth,2011,21(8):865-871.
摘要:體外循環(huán)是心內(nèi)直視手術(shù)重要的輔助手段,非外科性出血是體外循環(huán)心內(nèi)直視手術(shù)后的常見(jiàn)并發(fā)癥,可危及患者生命。體外循環(huán)造成的血小板功能損傷被認(rèn)為是體外循環(huán)心內(nèi)直視手術(shù)后非外科性出血的主要原因。體外循環(huán)引起血小板損傷的因素主要包括低溫、血液與氣體接觸、生物相容性、剪切力、魚精蛋白、肝素、麻醉藥物的使用、機(jī)血回輸、血液稀釋、體外循環(huán)流轉(zhuǎn)時(shí)間等。
關(guān)鍵詞:血小板損傷;體外循環(huán);非外科性出血
The Factors Affecting Platelet Function during Cardiopulmonary BypassCHIHao-yu1,2,LIUZhi-gang2,LIUXiao-cheng1,2.(1.ChineseAcademyofMedicalSciences&PekingUnionMedicalCollege,Beijing100730,China;2.DepartmentofCardiacSurgery,TEDAInternationalCardiovascularHospital,Tianjin300457,China)
Abstract:Cardiopulmonary bypass(CPB) is important to support the circulation during cardiac surgery.Postoperative nonsurgical bleeding of patients undergoing cardiac surgery with CPB is a common complication,which sometimes endangers patient′s life.Platelet dysfunction is considered to be one of the main contributors to nonsurgical bleeding after CPB.Contributing factors to platelet dysfunction during CPB include hypothermia,blood-air interaction,biocompatibility,shear stress,protamine,heparin,anaesthetic,hemodilution,duration of operation and shed blood retransfusion.
Key words:Platelet dysfunction; Cardiopulmonary bypass; Nonsurgical bleeding
收稿日期:2014-10-14修回日期:2014-12-27編輯:相丹峰
doi:10.3969/j.issn.1006-2084.2015.15.032
中圖分類號(hào):R54
文獻(xiàn)標(biāo)識(shí)碼:A
文章編號(hào):1006-2084(2015)15-2775-03